Generic Companies Gain Little From FDA Decision On Access To REMS Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency says the FDAAA does not allow a REMS to state that a brand sponsor cannot use a limited distribution program to prevent generic drug maker’s access to a product for bioequivalence testing.